Skip to main content
ALLO
NASDAQ Life Sciences

基因治疗公司拟公开发行1.75亿美元普通股

feedReported by GlobeNewswire
Sentiment info
Negative
Importance info
8
Price
$2.87
Mkt Cap
$744.742M
52W Low
$0.862
52W High
$4.46
Market data snapshot near publication time

summarizeSummary

基因治疗公司宣布拟公开发行1.75亿美元的普通股，并赋予承销商购买额外2.625亿美元的选项。这一重大资本募集代表着公司目前市值的约23.5%，此前公司宣布了其关键的2期ALPHA3试验的阳性中期无效性分析结果。虽然为临床试验阶段的生物技术公司募集资金是一种战略性举动，尤其是在获得积极数据之后，但对现有股东来说，这一重大股权稀释是一个重大的负面事件。交易者将密切关注发行的定价和完成情况，以及市场对这一重大稀释的反应，特别是在最近的积极临床新闻背景下。

在该公告发布时，ALLO的交易价格为$2.87，交易所为NASDAQ，所属行业为Life Sciences，市值约为$7.4亿。 52周交易区间为$0.86至$4.46。 这则新闻被评估为消极市场情绪，重要性评分为8/10。 来源：GlobeNewswire。

show_chartPrice Chart

Share this article

Copied!

feed ALLO - Latest Insights

ALLO
Apr 21, 2026, 8:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
Allogene Expands Pivotal ALPHA3 Cancer Trial to South Korea and Australia
Sentiment: Positive
View Wiseek Article
ALLO
Apr 20, 2026, 5:21 PM EDT
Filing Type: PRE 14A
Importance Score:
8
Allogene Therapeutics Seeks Shareholder Approval to Double Authorized Common Stock to 800 Million Shares
Sentiment: Neutral
View Wiseek Article
ALLO
Apr 16, 2026, 4:45 PM EDT
Source: Reuters
Importance Score:
8
Allogene Therapeutics Closes $200.4 Million Public Offering, Securing Capital
Sentiment: Neutral
View Wiseek Article
ALLO
Apr 15, 2026, 4:35 PM EDT
Filing Type: 8-K
Importance Score:
8
Allogene Therapeutics Prices $175M Public Offering at $2.00/Share Following Positive Trial Results
Sentiment: Negative
View Wiseek Article
ALLO
Apr 15, 2026, 4:33 PM EDT
Filing Type: 424B5
Importance Score:
8
Allogene Therapeutics Prices $175M Public Offering Following Positive Clinical Trial Results
Sentiment: Neutral
View Wiseek Article
ALLO
Apr 13, 2026, 4:09 PM EDT
Filing Type: 8-K
Importance Score:
8
Allogene Therapeutics Announces Proposed Public Offering Following Positive Trial Results
Sentiment: Neutral
View Wiseek Article
ALLO
Apr 13, 2026, 4:01 PM EDT
Source: GlobeNewswire
Importance Score:
8
Allogene Therapeutics Proposes $175 Million Public Offering of Common Stock
Sentiment: Negative
View Wiseek Article
ALLO
Apr 13, 2026, 7:45 AM EDT
Filing Type: 8-K
Importance Score:
9
Allogene Reports Highly Positive Interim Futility Analysis for Pivotal Phase 2 ALPHA3 Trial of Cema-cel in LBCL
Sentiment: Positive
View Wiseek Article
ALLO
Apr 13, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
9
Pivotal ALPHA3 Trial Shows Cema-Cel Achieves 58.3% MRD Clearance, Significantly Outperforming Observation Arm
Sentiment: Positive
View Wiseek Article
ALLO
Mar 12, 2026, 4:15 PM EDT
Source: Wiseek News
Importance Score:
9
Allogene Therapeutics Extends Cash Runway to Q1 2028, Narrows 2025 Net Loss to $190.9M
Sentiment: Positive
View Wiseek Article